Sponsor

Medpace, Inc.

Clinical research sponsor

Published trials34
Recruiting shown3
Roles1
SourceClinicalTrials.gov

Clinical trials

34 shown
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07702292 · collaborator · 2026-06-30
RECRUITING
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 · collaborator · 2026-02-23
RECRUITING
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07432633 · collaborator · 2026-02-19
RECRUITING
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate CancerNCT06516510 · collaborator · 2024-10-31
TERMINATED
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250 · collaborator · 2024-01-10
ACTIVE_NOT_RECRUITING
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid TumorsNCT05757492 · collaborator · 2023-04-26
TERMINATED
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer PatientsNCT05068726 · collaborator · 2023-01-05
TERMINATED
The Visceral Adiposity Measurement and Observation StudyNCT05383456 · collaborator · 2022-04-18
COMPLETED
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)NCT04622007 · collaborator · 2021-06-02
UNKNOWN
CXA-10 Study in Subjects With Pulmonary Arterial HypertensionNCT04053543 · collaborator · 2019-08-09
TERMINATED
Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010 · collaborator · 2019-04-09
COMPLETED
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's DiseaseNCT03625401 · collaborator · 2018-10-04
UNKNOWN
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)NCT03449524 · collaborator · 2018-08-01
TERMINATED
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile InfectionNCT03497806 · collaborator · 2018-05-01
COMPLETED
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive PatientsNCT03137264 · collaborator · 2017-10-24
COMPLETED
A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution FormulationNCT02672839 · collaborator · 2016-02-01
COMPLETED
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDDNCT02634177 · collaborator · 2016-01-01
COMPLETED
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer PatientsNCT02602067 · collaborator · 2015-11-01
TERMINATED
Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes PatientsNCT02542631 · collaborator · 2015-08-01
COMPLETED
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and HypertensionNCT02178098 · collaborator · 2014-06-16
COMPLETED
Pyridorin in Diabetic NephropathyNCT02156843 · collaborator · 2014-06-01
TERMINATED
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes MellitusNCT01919684 · collaborator · 2013-11-01
COMPLETED
VI-1121 for the Treatment Alzheimer's DiseaseNCT01428362 · collaborator · 2011-08-01
COMPLETED
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult SubjectsNCT01265394 · collaborator · 2010-12-01
COMPLETED
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary ProcedureNCT01252810 · collaborator · 2010-11-01
COMPLETED
Efficacy Study of Diazoxide Choline to Treat HypertriglyceridemiaNCT01211847 · collaborator · 2010-10-01
COMPLETED
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's DiseaseNCT01028053 · collaborator · 2009-12-01
COMPLETED
Evaluation of Patiromer in Heart Failure PatientsNCT00868439 · collaborator · 2009-04-01
COMPLETED
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)NCT00796367 · collaborator · 2008-12-01
COMPLETED
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy VolunteersNCT00785759 · collaborator · 2008-09-01
COMPLETED
Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 DiabetesNCT00734253 · collaborator · 2008-08-01
COMPLETED
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsNCT00563368 · collaborator · 2007-12-01
COMPLETED
Study of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsNCT00554216 · collaborator · 2007-11-01
COMPLETED
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid ConditionsNCT00553787 · collaborator · 2007-11-01
COMPLETED

Sponsor roles

collaborator34

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.